The estimated Net Worth of Pascal Touchon is at least 8.94 百万$ dollars as of 16 August 2024. Pascal Touchon owns over 3,038 units of Atara Biotherapeutics Inc stock worth over 582,755$ and over the last 5 years he sold ATRA stock worth over 1,721,987$. In addition, he makes 6,637,310$ as President、 Chief Executive Officer、 Director at Atara Biotherapeutics Inc.
Sign up
Pascal Touchon ATRA stock SEC Form 4 insiders trading
Pascal has made over 22 trades of the Atara Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,038 units of ATRA stock worth 20,142$ on 16 August 2024.
The largest trade he's ever made was selling 81,506 units of Atara Biotherapeutics Inc stock on 16 May 2024 worth over 50,534$. On average, Pascal trades about 12,294 units every 53 days since 2019. As of 16 August 2024 he still owns at least 70,127 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Pascal Touchon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Pascal Touchon biography
Dr. Pascal Touchon serves as President, Chief Executive Officer, Director of the Company since June 2019. Prior to joining the Company, Dr. Touchon has served in roles of increasing responsibility at Novartis Oncology, a business unit of Novartis International AG, a global pharmaceutical company, since August 2015, most recently as Global Head Cell & Gene Therapies Oncology and a member of the Oncology Executive Committee. Previously, Dr. Touchon was Global Head Strategy, Business Development & Licensing, Oncology and a member of the Oncology Executive Committee. Prior to joining Novartis Oncology, Dr. Touchon spent nearly thirty years in the pharmaceutical industry in various companies, countries and leadership roles, most recently with Servier SAS, a privately owned French pharmaceutical company, as Senior Executive Vice President, member of the company Executive Committee and Head of Business Development and Licensing. Dr. Touchon holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Supérieures Spécialisées (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).
What is the salary of Pascal Touchon?
As the President、 Chief Executive Officer、 Director of Atara Biotherapeutics Inc, the total compensation of Pascal Touchon at Atara Biotherapeutics Inc is 6,637,310$. There are no executives at Atara Biotherapeutics Inc getting paid more.
How old is Pascal Touchon?
Pascal Touchon is 57, he's been the President、 Chief Executive Officer、 Director of Atara Biotherapeutics Inc since 2019. There are 4 older and 13 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
What's Pascal Touchon's mailing address?
Pascal's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS, CA, 91320.
Insiders trading at Atara Biotherapeutics Inc
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over 58,305,463$ worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth 5,821,259$ . The most active insiders traders include Joel S Marcus、Eric Dobmeier、Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of 99,047$. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth 20,142$.
What does Atara Biotherapeutics Inc do?
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
What does Atara Biotherapeutics Inc's logo look like?
Complete history of Pascal Touchon stock trades at Atara Biotherapeutics Inc
Atara Biotherapeutics Inc executives and stock owners
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Pascal Touchon,
President, Chief Executive Officer, Director -
Joseph Newell,
Chief Operating Officer, Executive Vice President -
Utpal Koppikar,
Chief Financial Officer -
Dr. Pascal Touchon D.V.M.,
Pres, CEO & Director -
Dr. Kristin Yarema Ph.D.,
SVP & Chief Commercial Officer -
Joseph Newell,
Exec. VP & COO -
Utpal Koppikar,
CFO & SVP -
Dr. Jakob Dupont,
Head of Global R&D -
Carol Gallagher,
Lead Independent Director -
Eric Dobmeier,
Independent Director -
Matthew Fust,
Independent Director -
Beth Seidenberg,
Independent Director -
William Heiden,
Independent Director -
Roy Baynes,
Independent Director -
Eric Hyllengren,
Vice President, Investor Relations & Finance -
Maria Roncarolo,
Director -
Kristin Yarema,
Chief Commercial Officer -
K. Amar Murugan,
Senior Vice President, General Counsel -
Ronald Renaud,
Chairman of the Board -
Amie Krause,
Chief People Officer -
Kerry Beth Daly,
Head of Corp. Communications -
K. Amar Murugan,
Sr. VP & Gen. Counsel -
Dr. Anhco Nguyen,
Chief Scientific Officer -
Heather D Turner,
VP, General Counsel & Sec. -
Joel S Marcus,
Director -
Gad Soffer,
Chief Operating Officer -
Isaac E. Ciechanover,
Chief Executive Officer -
Derrell Porter,
SVP, Head of Global Commercial -
Joe Newell,
Chief Operations Officer -
Mitchall G. Clark,
Chief R & QA Officer -
Christopher Haqq,
Chief Medical Officer -
Mina Kim,
Senior VP & General Counsel -
Eckard Weber,
Director -
Viii Associates, L.P.Blair ...,
-
Perkins Caufield & Byers Xv...,
-
Partners Viii, L.P.Blair Ja...,
-
John Mcgrath,
Chief Financial Officer -
Dietmar Berger,
Global Head of R&D -
Ameet Mallik,
-
Jakob Dupont,
EVP, Head of R&D -
Charlene A. Banard,
EVP, Chief Technical Officer -
Amar Murugan,
EVP, Chief Legal Officer -
Jill Henrich,
EVP, Global Head RA & Quality -
Manher Joshi,
EVP, Chief Medical Officer -
Anh Co Nguyen,
President and CEO